Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL
Schorno Dean L exercised options for 4,600 Rigel Pharmaceuticals, Inc. shares (Form 4)
Traded Sep 1 to Sep 2, 2026 · Filed Sep 3, 2026
From Sep 1 to Sep 2, 2026, Schorno Dean L (EVP & Chief Financial Officer) exercised options for 4,600 Rigel Pharmaceuticals, Inc. shares at an average US$21.72 for US$99,929, leaving 82,962 shares. Filed Sep 3, 2026 (Form 4).
- Options exercised
- 4,600 shares
- Price
- US$21.72 average (US$12.70 to US$24.20)
- Value
- US$99,929
- Holding after
- 82,962 shares
- Trading plan
- No
- Role
- EVP & Chief Financial Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Common Stock | Shares withheld for tax | 928 | US$47.50 | 78,362 | Direct |
| Sep 2, 2026 | Common Stock | Option exercise | 694 | US$12.70 | 79,056 | Direct |
| Sep 2, 2026 | Common Stock | Option exercise | 620 | US$18.70 | 79,676 | Direct |
| Sep 2, 2026 | Common Stock | Option exercise | 2,000 | US$24.20 | 81,676 | Direct |
| Sep 2, 2026 | Common Stock | Option exercise | 1,286 | US$24.20 | 82,962 | Direct |
Source
Related
- Rigel Pharmaceuticals, Inc.
- Schorno Dean L
- Rigel Pharmaceuticals, Inc. shareholders
- Form 4 · Schorno Dean L · Jun 3, 2026
- Form 4 · Santos David A · Sep 3, 2026
- Form 4 · Rodriguez Raul R · Sep 3, 2026
- Form 4 · Furey Raymond J. · Sep 3, 2026
- Schedule 13G/A · Armistice Capital, LLC · Aug 14, 2026
- Schedule 13G/A · Soleus Capital Master Fund, L.P. · Aug 13, 2026